A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, cross-over study will evaluate the glucose
concentration and other glycemic parameters of efficacy, and the safety and tolerability and
pharmacokinetics of single oral doses of RO4998452 in patients with diabetes mellitus type 2.
On 3 treatment days a week apart, patients will each receive orally one of 2 dose levels of
RO4998452 or placebo. Anticipated time of study treatment is 3 weeks. Target sample size is
<50.